Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

The pharma group did not break down the details of the license to get control of STX-478, described as a next-generation PI3K alpha inhibitor for breast cancer and other advanced solid tumours ...

Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away to form a new entity with its remaining assets. Lilly’s bid to ...

STX-478 is a once-daily oral, mutant-selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. Eli Lilly and Company ...

STX-478 is a once-daily oral, mutant-selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. Eli Lilly and Company (NYSE: ...

STX-478 is a once-daily oral, mutant-selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. Eli Lilly and Company ...

In January 2025, Eli Lilly announced plans to acquire Scorpion Therapeutics’ experimental cancer therapy, STX-478, for up to $2.5 billion. The kinase inhibitors market is growing significantly and it ...

STX-478 is under clinical development by Scorpion Therapeutics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase ...